<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00481273</url>
  </required_header>
  <id_info>
    <org_study_id>AVIDA</org_study_id>
    <nct_id>NCT00481273</nct_id>
  </id_info>
  <brief_title>AVIDA The Vidaza® (Azacitidine) Patient Registry</brief_title>
  <acronym>AVIDA</acronym>
  <official_title>AVIDA The Vidaza® (Azacitidine) Patient Registry</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Celgene</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Celgene</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This registry is a prospective, multi-center, observational study compiling data on the
      natural history and management of patients receiving Vidaza, and will provide unique insights
      into the management of myelodysplastic syndromes (MDS) and other hematological disorders and
      the impact of these disorders on patients.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 31, 2006</start_date>
  <completion_date type="Actual">August 31, 2010</completion_date>
  <primary_completion_date type="Actual">August 31, 2010</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Vidaza usage</measure>
    <time_frame>Approximately 4 years</time_frame>
    <description>Describe current usage patterns for Vidaza in the community</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Concomitant care and treatment</measure>
    <time_frame>Approximately 4 years</time_frame>
    <description>Document common concomitant care procedures and treatments used in conjnction wtih Vidaza</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Duration and number of cycles</measure>
    <time_frame>Approximately 4 years</time_frame>
    <description>Correlate duration and number of Vidaza treatment cycles with clinical response as defined by 2006 International Working Group for Myeleodysplastic Syndrome</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Publication</measure>
    <time_frame>Approximately 4 years</time_frame>
    <description>Produce publications to support further clinical development and disseminate information on treatment best practices</description>
  </primary_outcome>
  <enrollment type="Actual">479</enrollment>
  <condition>Myelodysplastic Syndromes</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Azacitidine</intervention_name>
    <description>Physician's discretion</description>
    <other_name>Vidaza(R)</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Community-based hematology/oncology centers
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient who is deemed appropriate for treatment with Vidaza® by his or her clinician,
             but who has not already started receiving Vidaza® treatment.

          -  Patient who is able to read and speak English.

          -  Patient who is willing and able to provide informed consent.

          -  Patient who agrees to complete patient assessment questionnaires.

        Exclusion Criteria:

          -  Patients who are currently being treated with Vidaza®.

          -  Patients who are concurrently participating in a clinical trial.

          -  Patients unwilling or unable to complete the baseline and follow-up questionnaires.

          -  Patients who are deemed inappropriate for treatment with Vidaza®.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David L. Grinblatt, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>NorthShore University HealthSystem Research Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>AVIDA Registry Help</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>66210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Grinblatt DL, Sekeres MA, Komrokji RS, Swern AS, Sullivan KA, Narang M. Patients with myelodysplastic syndromes treated with azacitidine in clinical practice: the AVIDA registry. Leuk Lymphoma. 2015 Apr;56(4):887-95. doi: 10.3109/10428194.2014.935366. Epub 2014 Aug 20.</citation>
    <PMID>24956145</PMID>
  </reference>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 30, 2007</study_first_submitted>
  <study_first_submitted_qc>May 31, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 1, 2007</study_first_posted>
  <last_update_submitted>May 1, 2018</last_update_submitted>
  <last_update_submitted_qc>May 1, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 3, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>MDS</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Azacitidine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

